OpGen, Inc. (OPGN)

NASDAQ: OPGN · IEX Real-Time Price · USD
1.41
-0.14 (-9.03%)
At close: Mar 21, 2023, 4:00 PM
1.38
-0.03 (-2.13%)
After-hours: Mar 21, 2023, 7:44 PM EDT
-9.03%
Market Cap 4.54M
Revenue (ttm) 3.31M
Net Income (ttm) -40.73M
Shares Out 3.22M
EPS (ttm) -18.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 795,866
Open 1.50
Previous Close 1.55
Day's Range 1.31 - 1.54
52-Week Range 0.93 - 17.56
Beta -0.22
Analysts Sell
Price Target 32.23 (+2,185.82%)
Earnings Date Apr 4, 2023

About OPGN

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also com... [Read more]

Sector Healthcare
IPO Date May 5, 2015
Employees 91
Stock Exchange NASDAQ
Ticker Symbol OPGN
Full Company Profile

Financial Performance

In 2021, OpGen's revenue was $4.31 million, an increase of 2.17% compared to the previous year's $4.21 million. Losses were -$41.97 million, 60.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for OPGN stock is "Sell." The 12-month stock price forecast is $32.23, which is an increase of 2,185.82% from the latest price.

Price Target
$32.23
(2,185.82% upside)
Analyst Consensus: Sell
Stock Forecasts

News

OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infect...

2 weeks ago - GlobeNewsWire

OpGen Announces Exercise of All Prefunded Warrants

ROCKVILLE, Md., Feb. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

1 month ago - GlobeNewsWire

OpGen subsidiary Ares Genetics announces granting of key patent in China

ROCKVILLE, Md., Jan. 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infecti...

1 month ago - GlobeNewsWire

OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

ROCKVILLE, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

2 months ago - GlobeNewsWire

OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project

Successful delivery of milestones triggers milestone payment Successful delivery of milestones triggers milestone payment

2 months ago - GlobeNewsWire

OpGen Announces Closing of $7.5 Million Public Offering

ROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

2 months ago - GlobeNewsWire

OpGen Announces Pricing of $7.5 Million Public Offering

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

2 months ago - GlobeNewsWire

OpGen Announced 1-for-20 Reverse Stock Split

ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

2 months ago - GlobeNewsWire

Why Is OpGen (OPGN) Stock Up 148% Today?

OpGen (NASDAQ: OPGN) stock is rocketing higher on Tuesday after posting results from its Unyvero urinary tract infections ( UTI) clinical trial. This clinical trial covered Unyvero UTI Panel's abili...

3 months ago - InvestorPlace

OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

ROCKVILLE, Md., Dec. 13, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

3 months ago - GlobeNewsWire

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

4 months ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 202...

5 months ago - GlobeNewsWire

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infe...

5 months ago - GlobeNewsWire

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

ROCKVILLE, Md. and BASEL, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostic...

5 months ago - GlobeNewsWire

OpGen Announces Closing of $3.38 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

6 months ago - GlobeNewsWire

OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

ROCKVILLE, Md., Oct. 03, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

6 months ago - GlobeNewsWire

OpGen Announces $3.38 Million Registered Direct Offering

ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

6 months ago - GlobeNewsWire

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

ROCKVILLE, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics t...

6 months ago - GlobeNewsWire

OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference

This in-person and virtual (hybrid) conference to be held September 12-14, 2022 This in-person and virtual (hybrid) conference to be held September 12-14, 2022

7 months ago - GlobeNewsWire

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infecti...

7 months ago - GlobeNewsWire

OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory

ROCKVILLE, Md., Aug. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to he...

7 months ago - GlobeNewsWire

OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update

ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to...

7 months ago - GlobeNewsWire

OpGen to Provide Business Update and Financial Results for the Second Quarter 2022 on August 11th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 20...

8 months ago - GlobeNewsWire

OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven

ROCKVILLE, Md., July 26, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”) announced today that its subsidiary Ares Genetics GmbH (Ares Genetics), which strives to become a leader in bacter...

8 months ago - GlobeNewsWire

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

ROCKVILLE, Md., July 08, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infe...

9 months ago - GlobeNewsWire